|Articles|July 31, 2017
LabCorp to Acquire Chiltern for Approximately $1.2 Billion
Advertisement
LabCorp-global life sciences company-and specialty CRO, Chiltern, announced that LabCorp will acquire Chiltern in an all-cash transaction for approximately $1.2 billion. Following the completion of the transaction, Chiltern will become part of LabCorp’s Covance segment.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?
2
Answering the Sustainability Call: Digital Health Technologies and eCOA
3
KRI Overload: When More Isn’t Better
4
Applied Clinical Trials' 2025 State of the Industry Survey
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
